Jasmine Cui – Founder & CEO, Innocare
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
Address: Suite 2202, Level 22, 141 Walker Street, North Sydney NSW 2060,Australia
Tel: +61 2 9922 5111
Web: http://www.asmi.com.au/home/
ASMI is the peak body representing companies involved in the manufacture and distribution of consumer healthcare products in Australia. Since its establishment in 1974, the Association has focussed its efforts on supporting the progress and development of the Self Care products industry, including both OTCs and complementary products.
Our purpose is to promote the best interests of our Members through negotiation, debate and cooperation with a wide range of stakeholders in our own region and around the world. We also gather the best and most current information from diverse sources and disseminate it to our Members to alert them to potential issues that may affect their product or its market.
ASMI is a member of the World Self-Medication Industry (WSMI) and our President and Executive Director sit on the Board of that organisation. WSMI is a non-government organisation made up of over 50 member associations located on all continents of the World, with affiliations to the World Health Organization (WHO). Our membership of WSMI enables us to track and contribute to international trends and developments in consumer healthcare.
ASMI – the voice of the consumer Self Care products industry, driving a credible and expanding evidence-based self-medication market to generate cost-effective health solutions and improved public health outcomes.
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
Medaxes – the Belgian industry association for companies producing generic and biosimilar medicines, as well as other off-patent medicines and self-care products – welcomed a new CEO in 2022, Jasmien…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
See our Cookie Privacy Policy Here
